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We have determined the systemic biodistribution of
the hormone leptin by PET imaging. PET imaging
using 18F- and 68Ga-labeled leptin revealed that, in
mouse, the hormonewas rapidly taken up bymegalin
(gp330/LRP2), a multiligand endocytic receptor
localized in renal tubules. In addition, in rhesus
monkeys, 15% of labeled leptin localized to red
bone marrow, which was consistent with hormone
uptake in rodent tissues. These data confirm amega-
lin-dependent mechanism for renal uptake in vivo.
The significant binding to immune cells and blood
cell precursors in bone marrow is also consistent
with prior evidence showing that leptin modulates
immune function. These experiments set the stage
for similar studies in humans to assess the extent
to which alterations of leptin’s biodistribution might
contribute to obesity; they also provide a general
chemical strategy for 18F labeling of proteins for
PET imaging of other polypeptide hormones.
INTRODUCTION
Leptin is a 16 kDa protein hormone secreted by adipocytes that
regulates body weight by reducing food intake and increasing
energy expenditure (Coll et al., 2007; Friedman and Halaas,
1998). Leptin also signals nutritional status to several other phys-
iological systems and modulates their function. The leptin
receptor is a cytokine family receptor with several isoforms
that are generated by alternative splicing. Genetic evidence
has indicated that leptin’s biologic effects are principally the
result of binding to the LepRb isoform, which is the only splice
variant of the leptin receptor that expresses all of the motifs
required for signal transduction. Genetic evidence has further
suggested that this isoform is necessary for leptin to exert its
weight-suppressing effects. LepRb is expressed primarily in
brain and on hematopoietic and immune cells, while the other
splice variants show a broad tissue distribution, including148 Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inkidney, liver, lung, and spleen (Fei et al., 1997). While leptin
signaling in the central nervous system is both necessary (Cohen
et al., 2001) and sufficient (de Luca et al., 2005) to elicit leptin’s
metabolic effects, direct actions on peripheral tissues have
also been described (Lord et al., 1998; Morioka et al., 2007;
Sierra-Honigmann et al., 1998).
In this study, we set out to further assess the biodistribution
and metabolism of leptin using positron emission tomography
(PET) imaging. PET is well suited for studies of the biodistribution
of hormones due to its millimeter scale resolution, high sensi-
tivity, and ease of quantification (Bailey et al., 2005). While
a previous report used PET imaging to study the CNS distribution
of leptin following intrathecal injection (McCarthy et al., 2002),
PET imaging has not been used to comprehensively study
leptin’s systemic biodistribution. Here, we describe the develop-
ment of two positron-labeled leptin tracers, 18F-FBA-leptin and
68Ga-DOTA-leptin. The use of PET in mutant mice has confirmed
that leptin metabolism by renal cortex is mediated by megalin
and not LepR, despite the high levels of LepR gene expression
in this tissue. We also show a high level of leptin uptake in hema-
topoietic tissues in rodents and monkeys, consistent with a role
for leptin in modulating the physiology of hematopoiesis and/or
immune function.
RESULTS
Development of Leptin Tracers
Two leptin tracers were generated: 18F-FBA-leptin and 68Ga-
DOTA-leptin, which label the C terminus or amino groups,
respectively. Mutagenesis studies have identified residues of
leptin that are required for receptor binding and activation (Peel-
man et al., 2004; Verploegen et al., 1997), and overall these
studies indicate that lysine residues of the protein as well as
the C and N termini of the molecule are not critical for receptor
binding and activation (Zhang et al., 1997). We thus reasoned
that either an amine-directed or a site-specific C-terminal
labeling strategy would produce a labeled leptin derivative
with unaltered bioactivity and, moreover, that consistent results
for both tracers would confirm the bona fide distribution of the
hormone (Figure 1A). 68Ga-DOTA-leptin was labeled usingc.
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employed a recently developed strategy that can specifically
label the C terminus of proteins in a site-specific manner, using
expressed protein ligation followed by an oximation reaction
(Figure S1) (Flavell et al., 2008). This tracer, named 18F-FBA-lep-
tin, retains biological activity and, because 18F is a lower-energy
positron emitter, allows for high-resolution micro-PET imaging
(Flavell et al., 2008).
Leptin was labeled with 68Ga using the chelator DOTA
(Figure 1B). An average of four DOTA moieties was incorporated
per leptin molecule using DOTA-NHS (De Leo´n-Rodrı´guez and
Kovacs, 2008) (Figure 1C). The modified protein retained its
ability to activate STAT3-dependent LepR signaling in a cell line
stably transfected with leptin receptor (Figure 1D) and was
also able induce weight loss in leptin-deficient (ob/ob) mice with
similar potency to unmodified recombinant leptin (Figure 1E). The
decay-corrected radiochemical yield of 68Ga-DOTA-leptin was
25.7% ± 4.9% SD (n = 30, specific activity of 5.5–11 GBq/mmol)
Figure 1. Design, Synthesis, and Biological
Activity of the Tracer 68Ga-DOTA-Leptin
(A) Two surface-rendered views of the structure of
leptin (PDB ID 1AX8). Residues that are essential
for LepR activation are rendered in yellow, while
the amines (the sites of labeling in 68Ga-DOTA-lep-
tin) are rendered in red, and the C terminus (the site
of labeling in 18F-FBA-leptin) is rendered in blue.
(B) Schematic of 68Ga-DOTA-leptin tracer.
(C) ESI-MS of DOTA-leptin revealing an average of
four copies of DOTA per leptin molecule.
(D) In vitro bioactivity of DOTA-leptin was
compared to recombinant leptin using a cell line
stably expressing leptin receptor (LepRb) and
a luciferase reporter under STAT3-responsive
element. The EC50 for activation was 0.42–
0.55 nM for recombinant leptin and 0.54–0.66
nM for DOTA-leptin (95% confidence intervals,
n = 2 per group ± SD).
(E) DOTA-leptin induces weight loss to a similar
extent as recombinant leptin in ob/ob mice (n = 4
per group, mean ± SEM, dose = 450 ng/hr).
(F) Radiochemical RP-HPLC analysis of purified
68Ga-DOTA-leptin (blue) and serum recovered
from a mouse 30 min after injection with 68Ga-
DOTA-leptin.
(G) Cell binding assay of 68Ga-DOTA-leptin using
a 293 cell line expressing LepRb, in the presence
or absence of 1 mM competing recombinant leptin
(n = 3, mean ± SEM).
(Figure S2), with a product that was greater
than 90% pure (Figure 1F). The tracer was
stable in vivo, as assessed by radiochem-
ical HPLC analysis of the serum recovered
from a mouse injected 30 min prior (Fig-
ure 1F). Finally, the 68Ga labeling proce-
dure did not abrogate receptor binding
activity, as the labeled protein bound to
the cell line expressing LepR, and this
binding could be displaced by excess
competing cold leptin (Figure 1G). As
mentioned above, 18F-FBA-leptin was
labeled, and the tracer was previously validated in vitro and
in vivo as described (Flavell et al., 2008). Overall, we have devel-
oped two positron-emitting leptin tracers using complementary
labeling chemistries and isotopes, one of which is site specific,
and both tracers retained bioactivity in vivo and in vitro.
Whole-Body PET Scans
We analyzed the biodistribution of leptin in mice and rats using
both 68Ga-DOTA and 18F-FBA tracers. PET imaging of both
tracers after injection into ob/ob mice revealed that leptin accu-
mulates principally in the kidneys and, to a much lesser extent, in
several other visceral organs, including liver and spleen, as well
as the head (Figures 2A and 2B). Uptake of the tracers was not
observed in fat and brain. The superior resolution of 18F
compared to 68Ga further allowed us to visualize the accumula-
tion of the tracer in the renal cortex in mice (Figures 2B and 2D).
This finding was also confirmed using 68Ga-DOTA-leptin in rats
(Figure 2C). These data indicated that leptin is filtered by theCell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc. 149
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PET Imaging of Leptin Metabolism and Distributionkidney and taken up by renal tubular cells, where it is likely to be
metabolized, a possibility consistent with previous reports
(Cumin et al., 1996; Klein et al., 1996; Meyer et al., 1997; Zeng
et al., 1997).
Quantitative Analysis of Kidney Uptake
Kinetic analysis of uptake with our tracers in the kidney revealed
that 68Ga radioactivity remained in the kidney for an extended
period after 68Ga-DOTA-leptin injection (i.e., the tracer and/or
its metabolites are trapped intracellularly), while 18F-FBA-leptin
did not, consistent with previous reports using tracers labeled
with similar methods (Figure S3) (Schottelius et al., 2004; Tsai
et al., 2001). Thus, 68Ga-DOTA-leptin was used in a series of
quantitative kinetic studies.
Thirty minutes after injection of the tracer, 68.2% ± 1.5% was
localized to the kidney (Figure 3C). Radiochemical HPLC anal-
ysis of kidney extracts from mice injected with the tracer
Figure 2. Whole-Body PET Images of Mice and
Rats Reveal that Leptin Is Taken Up in the Cortex
of the Kidney
(A) Whole-body PET maximum intensity projection (MIP)
image of a leptin-deficient (ob/ob) mouse injected with
68Ga-DOTA-leptin. Renal uptake of leptin in ob/ob mice
is 65.1% ± 3.5% while the bladder is only 2.2% ± 0.2%
over 30 min. Uptake in other organs is lower than this
per volume.
(B) Whole-body PET coronal MIP image of an ob/ob
mouse injected with 18F-FBA-leptin, with inset of kidneys
with lowered contrast, revealing uptake of the hormone
in the renal cortex.
(C) Whole-body PET coronal MIP of a Sprague-Dawley rat
injected with 68Ga-DOTA-leptin, with inset with lowered
contrast, revealing uptake of the hormone in the cortex
of the kidney. The images are overexposed to reveal areas
with a lower level of uptake.
(D) Simplified diagram of renal anatomy.
showed a peak eluting at 3 min, in contrast to
intact leptin, which elutes at 21.6 min, indicating
that the leptin was degraded in this organ
(Figure 3A). When the tracer was coinjected
with a 30-fold excess of cold ligand, 23.7% ±
2.2% of the leptin was displaced from the
kidney and instead appeared in the bladder
(Figure 3C). Radiochemical HPLC analysis of
the urine of these animals revealed a peak
eluting at 21.6 min, indicating that intact leptin
is displaced from the kidney receptors (Fig-
ure 3B). These results suggested that leptin
uptake by the renal tubular cells is mediated
by a saturable receptor-mediated mechanism
and that leptin is degraded after being taken
up by these cells.
Kidney Uptake of Leptin in Ob/Ob
and Ob/Ob-LepRD Mice
LepR is expressed in the kidney, raising the
possibility that it might be responsible for
the renal uptake of leptin (Fei et al., 1997; Hama et al.,
2004). In order to test this hypothesis, we compared the
renal uptake of the tracer in wild-type mice, leptin-deficient
(ob/ob) mice, and mice with a null mutation of the leptin
receptor. In order to address the possible confounding effect
of secondarily elevated high endogenous leptin levels in
LepR-deficient mice (which have a null LepR mutation),
LepRD mutant mice were mated to ob mice, and the studies
were performed in mice that carried mutations in both leptin
and its receptor (referred to as ob/ob-LepRD mice) (Cohen
et al., 2001). This allows a direct comparison of the biodistri-
bution of the leptin tracer in ob/ob mice ± the leptin receptor.
Time activity curves of kidney uptake in these three experi-
mental groups are identical (Figure 3D). These data sug-
gested that the renal uptake of leptin was not mediated by
the leptin receptor and that rather a different receptor was
responsible.150 Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc.
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Kidney Knockout Mice
We next considered the possibility that leptin uptake by the kidney
was mediated by megalin (gp330/LRP2). Megalin is a high-molec-
ular-weight multiligand receptor that is expressed in the proximal
convoluted tubule in the kidney and other tissues (Christensen
and Birn, 2002). Previous studies have shown that megalin medi-
ates the renal uptake of several hormones. In addition, previous
studies have also shown that leptin is capable of binding to mega-
lin in vitro with an affinity of 200 nM (Hama et al., 2004). In order to
test the role of megalin in renal uptake of leptin, we studied mice
with a kidney-specific megalin knockout (termed megalinlox/lox
ApoECre) (Leheste et al., 2003). The renal expression of the
receptor is reduced to10% of normal levels in the megalinlox/lox
ApoECre mice (Leheste et al., 2003).
Leptin is undetectable in the urine of wild-type rodents, so we
began by measuring the urine levels of leptin in the knockout
mice by ELISA. Leptin levels in the urine of megalinlox/loxApoECre
mice were 16.7 ± 2.9 ng/ml (n = 4 ± SEM), indicating a significant
excretion of leptin in urine in the knockout mice (Figure 4A). The
urinary leptin was intact, as confirmed by western blotting
(Figure 4B).
These results suggest that leptin is filtered by the renal
glomerulus and taken up in the proximal convoluted tubule in
Figure 3. Blocking Experiments of Leptin Uptake in
the Kidney in Wild-Type Mice and Analysis of Uptake
in LepR-Deficient Animals
(A) Coronal MIP of a C57BL/6 wild-type mouse injected with
68Ga-DOTA-leptin, with inset of radiochemical RP-HPLC
analysis of homogenized kidneys 1 hr after injection with
68Ga-DOTA-leptin.
(B) Coronal MIP of a C57BL/6 wild-type mouse coinjected with
68Ga-DOTA-leptin and 650 mg leptin, with inset of a radiochem-
ical RP-HPLC analysis of the urine 30 min postinjection.
(C) Time activity curves of the kidney of C57BL/6 wild-type
mice injected with 68Ga-DOTA-leptin in the presence or
absence of 650 mg leptin. All data are reported as means (n =
3) ± SEM. Statistical significance of the difference between
the two groups was assessed by Student’s t test, p < 0.01
for all time points.
(D) A comparison of the uptake of 68Ga-DOTA-leptin in the
kidneys of wild-type C57BL/6, ob/ob, and ob/ob-LepRDmice.
a megalin-dependent manner. To confirm this, we
performed PET imaging of megalinlox/loxApoECre
mice using 68Ga-DOTA-leptin. These studies
showed that, similar to the effect of adding an
excess of cold leptin, the level of the tracer in the
bladder of megalinlox/loxApoECre mice is significantly
increased and that the uptake by the kidney is sig-
nificantly reduced when compared to littermate
controls (Figures 4C, 4D, 4F, and 4G). Note that
there is some residual uptake of the tracer in the
renal cortex of megalinlox/loxApoECre mice, attribut-
able to the fact that the megalin knockout is incom-
plete in kidney (Figure S4). Radiochemical HPLC
analysis of the urine from a megalinlox/loxApoECre
mouse revealed the characteristic peak of intact
leptin (Figure 4E). In aggregate, these data show
that leptin is freely filtered by the glomerulus and that megalin is
required for the uptake and metabolism of the hormone in the
proximal convoluted tubule.
Leptin Uptake Is Mediated by Megalin In Vitro
Megalin also mediates the uptake of other hormones as well as
aminoglycoside antibiotics. We studied the degradation of 125I-
leptin by megalin-expressing L2 cells, as previously described
(Hama et al., 2004). Similar to other peptides, 125I-leptin is
degraded by these cells. In L2 cells, leptin degradation is
inhibited in a dose-dependent manner by cold leptin (Figure 4H).
Leptin degradation is also inhibited by the known megalin inhib-
itor, receptor-associated protein (RAP) (Figures S5 and 4H)
(Christensen and Birn, 2002). These data confirm that leptin is
degraded after receptor-mediated uptake by megalin in vitro.
Several peptides and proteins, including parathyroid hormone
(PTH), insulin, prolactin, and apolipoprotein J (ApoJ)/clusterin,
were also able to inhibit the degradation, while other ligands
such as aminoglycoside did not (Figures 4I and 4J). This result
suggests that leptin likely binds to the same site of megalin as
PTH, insulin, prolactin, and ApoJ. Overall, these in vivo and
in vitro data confirm that leptin metabolism is the result of binding
to megalin followed by the intracellular degradation of the
hormone.Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc. 151
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(A) ELISA of leptin in the urine of the indicated mouse strains. The dotted line represents the limit of detection of the assay (n = 3 ± SEM; statistical significance of
difference between megalinlox/loxApoECre and megalinlox/lox, p < 0.001).
(B) Anti-leptin western blot of the urine of megalinlox/loxApoECre and megalinlox/lox controls.
(C and D) Coronal MIP of a megalinlox/lox control mouse (C) injected with 68Ga-DOTA-leptin and of a megalinlox/loxApoECre mouse (D) injected with 68Ga-DOTA-
leptin.
(E) Radiochemical RP-HPLC analysis of urine recovered from a megalinlox/loxApoECre mouse, which was injected with 68Ga-DOTA-leptin.
(F and G) Time activity curves of the uptake in the kidney (F) and bladder (G) of 68Ga-DOTA-leptin in megalinlox/loxApoECre and megalinlox/lox mice. All data are
reported as mean ± SEM (n = 3). Statistical significance of megalin kidney KO versus lox controls: *p < 0.05, **p < 0.01.
(H) Leptin is degraded by an L2 yolk sac tumor cell line, and the degradation can be inhibited by competing cold leptin or receptor-associated protein (RAP,
100 mg/ml). Data are reported as mean ± SEM (n = 4).
(I and J) Degradation of leptin by L2 cells can be inhibited by some megalin ligands (J) but not others (I). Data are reported as mean ± SEM (n = 3).152 Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc.
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(A–D) 125I-leptin (8–12 KBq) was injected into the tail vein of the indicated mouse strains. The animals were sacrificed 15 min postinjection; the indicated tissues
were removed and weighed, and the radioactivity was counted. Standard uptake value on the y axis is defined as the percent injected dose per gram of tissue
divided by percent injected dose per milligram of blood. This analysis is used to correct for the varying levels of leptin in the blood in the different animal groups
(Table S2). Results are represented as means ± SEM (n = 3–4 per experimental group). Statistical significance between groups was assessed by Student’s t test
(*p < 0.05, **p < 0.01). Uptake in organs compared between wild-type animals and wild-type animals with 650 mg leptin coinjection is shown in (A). Uptake in
organs compared between ob/ob mice, ob/ob mice with 650 mg leptin coinjection, and ob/ob-LepRD mice is shown in (B)–(D).Biodistribution Analysis in Mice
The absence of a leptin signal in other tissues after PET imaging
does not exclude the possibility that leptin binds there, as the
sensitivity of PET imaging is limited by the total number of
binding sites and the specific activity of the tracer. In order to
further assess the extent to which leptin could bind to LepR in
other tissues, we performed biodistribution analysis using
125I-leptin. In this experiment, a small amount (less than 100 ng,
versus 20–30 mg in a PET experiment [Table S2]) of 125I-leptin
was injected ± an excess of cold leptin, and animals were sacri-
ficed 15 min later, after which the radioactivity was quantitated in
tissues.CeWe compared four groups of mice: wild-type, ob/ob, LepRD,
and the aforementioned ob/ob-LepRD (Table S1). As above,
the ob/ob-LepRD were used so that we could robustly analyze
leptin uptake without the confounding effect of hyperleptinemia,
which could competitively inhibit leptin binding. Wild-type mice
showed saturable uptake of 125I-leptin in the spleen, lung, liver,
and intact femur (Figure 5A). This was confirmed in studies of
ob/ob mice, ob/ob mice with competing cold leptin injection,
and ob/ob-LepRD mice, where we found saturable, LepR-
dependent uptake of leptin in the spleen, lung, liver, femur, fat,
and brain (Figures 5B–5D). Collectively, these data suggest
that LepR is required for leptin binding at high levels in thell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc. 153
Cell Metabolism
PET Imaging of Leptin Metabolism and DistributionFigure 6. PET Imaging Study of Leptin Biodistribution in Rhesus Macaques
(A and B) Coronal MIP acquired 10 min after injection of 15 MBq 68Ga-DOTA-leptin (A) or 18F-FBA-leptin (B).
(C) Coronal MIP of a rhesus macaque acquired 10 min after injection of 15 MBq 68Ga-DOTA-leptin, with pretreatment with 1 mg of rhesus leptin 5 min before
radiotracer injection.154 Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc.
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brain. The binding of leptin in spleen and femur is consistent with
the previous reports of direct effects of leptin on immune and
hematopoietic cells (Bennett et al., 1996; Cioffi et al., 1996; Far-
ooqi et al., 2002; Gainsford et al., 1996; Umemoto et al., 1997).
This possibility was further assessed in studies of nonhuman
primates (see below).
PET/CT of Leptin Biodistribution in Rhesus Macaques
We next performed PET/CT imaging in rhesus macaques. In
addition to providing a potential basis for initiating PET imaging
in humans, the use of monkeys for PET imaging often provides
greater sensitivity, owing to their larger size and the correspond-
ing increase in the number of binding sites. PET imaging using
both 68Ga-DOTA-leptin and 18F-FBA-leptin revealed that the
tracer was again concentrated in the cortex of the kidney,
consistent with a megalin-dependent uptake mechanism (Fig-
ure 6D). In addition to the kidney, there was highly significant lep-
tin binding in sphenoid bone, mandible, vertebral bodies,
sacrum, sternum, and the head of the humeri and femurs.
Binding of leptin to these sites and not adjacent structures is
clearly evident in the 3D reconstruction offered by the video file
(Figures 6A, 6B, and 6E–6H; Movies S1 and S2). This pattern
of uptake reproduces the known pattern of red bone marrow in
adult primates (Blebea et al., 2007). Pretreatment of the monkey
with 1 mg of unlabeled rhesus leptin or murine leptin, but not
equimolar amounts of albumin (3.3 mg), as a negative control
(Figure S6) 5 min prior to scanning blocked this signal, indicating
that leptin binding at these sites is saturable and likely to be LepR
mediated (Figures 6C, S7, and S8; Movies S3 and S4). At early
time points (10–25 min postinjection), a significant fraction of lep-
tin can be seen in the blood pool fraction, including high levels in
the chambers of the heart and great vessels. At later time points,
nearly all of the leptin has localized in the bone marrow and
kidney or in kidney alone when competing leptin is present (Fig-
ure S9; Movies S3–S6). 18F-FBA-leptin initially follows a similar
biodistribution to 68Ga-DOTA-leptin, but as a consequence of
tissue uptake and degradation (see above), its labeled metabo-
lites appear in the bladder (Figure S9).
Quantification of the uptake revealed that 15.8% and 16.4% of
68Ga-DOTA-leptin and 14.1% of 18F-FBA-leptin localized to and
was retained in the bone marrow in a saturable manner, while
there was no saturable uptake in the heart (Figures 6I and 6J).
These data show that, in addition to kidney, there is substantial
leptin binding to red bone marrow in rhesus macaques, an
observation that is consistent with leptin’s known effects on
immune function.
DISCUSSION
Here we report the development, using complementary labeling
chemistries and isotopes, of two fully bioactive tracers for
studying leptin biodistribution and their application to PETCeimaging in rodents and nonhuman primates. The methods
described are widely applicable to study the in vivo biodistribu-
tion of peptides and protein hormones. The use of two tracers
validates the results and also provides complementary informa-
tion, with 18F-FBA-leptin allowing for high-resolution micro-PET
imaging (Figure 2B) and 68Ga-DOTA-leptin providing a platform
for a quantitative and kinetic analysis of leptin uptake (Figures
3A, 3C, 4F, 4G, and S3).
Whole-body PET images using our tracers revealed a similar
biodistribution in mice and rats with highly significant uptake in
the renal cortex (Figures 2B–2D). This micro-PET rodent study
thus provided an opportunity to directly quantify leptin metabo-
lism in the kidney, where there was a high level of uptake and
a similar biodistribution pattern in mice, rats, and rhesus
macaques (Figures 2 and 6D). In both humans and rodents, lep-
tin has a short half-life, and the kidneys have been suggested to
be the major site of leptin metabolism, accounting for over 80%
of all clearance from plasma (Cumin et al., 1996; Klein et al.,
1996; Meyer et al., 1997; Vila` et al., 1998; Zeng et al., 1997).
The finding of rapid and identical kidney uptake in several mouse
strains, rats, and monkeys, with approximately 50% of the total
hormone appearing in the kidney 3 min postinjection, is consis-
tent with this evidence, suggesting that leptin is metabolized
by the kidney. The clearance of peptide low-molecular-weight
hormones such as leptin by the kidney may have clinical signifi-
cance, because end-stage renal disease (ESRD) causes
increased leptin levels (Merabet et al., 1997) and could thus
contribute to the anorexia of ESRD.
Both the long (LepRb) and one of the short (LepRa) isoforms of
leptin receptor are expressed in kidney, mainly at the loop of
Henle (Hama et al., 2004), and both forms are capable of medi-
ating the internalization of leptin in vitro (Hileman et al., 2000).
However, the observation that renal uptake of leptin is identical
in mice with or without the leptin receptor suggested that its
uptake was mediated by a different receptor. We thus tested
whether this uptake was mediated by megalin.
Megalin is highly expressed in the proximal convoluted tubule
of the renal cortex and mediates the endocytosis of several
ligands, including hormones and their precursors (PTH, insulin,
prolactin, EGF, thyroglobulin), vitamin binding proteins (Vit-D
binding protein, retinol binding protein, transcobalamin), and
other carrier proteins (hemoglobin, myoglobin, albumin, lactofer-
rin, transthyretin) (Christensen and Birn, 2002). Mice with a
kidney-specific knockout of megalin (megalinlox/loxApoECre)
show reduced renal uptake of several megalin ligands (de Jong
et al., 2005; Leheste et al., 2003; Raila et al., 2005). Several lines
of evidence confirm that megalin (gp330/LRP2) and not LepR
mediates leptin metabolism in the kidney in vivo. First, leptin
directly binds to megalin with an affinity of 200 nM (Hama
et al., 2004). Furthermore, there are increased levels of intact lep-
tin in the urine of megalinlox/loxApoECre mice, and the uptake of
leptin in the kidneys in these animals is reduced in a PET imaging
assay. Finally, we showed that leptin can be degraded by the(D) Coronal PET/CT fusion revealing uptake of the tracer in the cortex of the kidney.
(E) Sagittal PET/CT fusion revealing uptake of the tracer in the vertebral bodies, sternum, and liver; the tracer is also present in the blood pool (heart).
(F–H) Axial PET/CT sections through the sphenoid bone of the base of the skull (F), the L4 vertebral body (G), and the sacrum (H).
(I and J) Time activity curves of 68Ga-DOTA-leptin uptake in the bone marrow (I) and heart (J). The y axis on the time activity curves represents the percent of total
injected dose localized to that tissue. Data are reported as mean ± SD (n = 2).ll Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier Inc. 155
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that the degradation can be inhibited by other known megalin
ligands (Figures 4H and 4J). Thus, megalin and not LepR is
responsible for the binding and uptake of leptin by the renal
tubular cells after filtration of the protein by the glomerulus.
Once leptin is taken up by the renal tubular cells, it is degraded.
These results also raise the possibility that megalin could play
a role in other aspects of leptin physiology. Megalin is expressed
in lung, intestine, thyroid, parathyroid, placenta, endometrium,
yolk sac, epididymis, ovary, and, importantly, in brain microves-
sels and choroid plexus (Zlokovic et al., 1996). These latter two
anatomical structures comprise the blood-cerebrospinal fluid
barrier (Christensen and Birn, 2002), suggesting that megalin,
expressed at lower level (and mass) than in the kidney, could
play a role in the transport or metabolism of leptin in the brain,
the mechanism for which has not been elucidated. It was
recently shown that in rats, the delivery of lentiviral vectors con-
taining siRNA directed against megalin reduced leptin levels in
cerebrospinal fluid, as assessed by western blot (Dietrich et al.,
2008). Our finding that leptin is cleared in a megalin-dependent
manner in the renal cortex is consistent with the possibility that
megalin may play a role in the uptake or metabolism of leptin
in additional sites, a possibility that can be tested in mice with
megalin knockouts in other organs, now underway.
The biodistribution and PET experiments of leptin reveal a high
level of uptake in tissues undergoing active hematopoiesis,
specifically the bone marrow in rhesus monkeys and the bone
marrow and spleen in mice (Galloway and Zon, 2003). This
includes the demonstration that leptin binding in the bone marrow
and spleen is LepR dependent in mice and the fact that bone
marrow binding of leptin in rhesus macaques can be saturated
at only 0.1 mg/kg injected dose of leptin. These results are
consistent with known LepR expression in hematopoietic precur-
sors (Bennett et al., 1996; Cioffi et al., 1996) and the observation
that leptin has direct effects on hematopoietic precursors and
bone marrow stromal cells in vitro (Gainsford et al., 1996; Thomas
et al., 1999; Umemoto et al., 1997). In addition, leptin-deficient
mice and humans are immunocompromised, in a manner that
can be reversed with leptin treatment, revealing that leptin’s
role in regulating the immune system and hematopoiesis is
required for normal immune and hematopoietic function (Clay-
combe et al., 2008; Farooqi et al., 2002; Lord et al., 1998; Palmer
et al., 2006). While the similar data in all species tested suggest
that leptin uptake in the bone marrow in rhesus monkeys is
LepR dependent, further experiments are necessary to confirm
this observation. A characterization of the cell types responsible
for leptin uptake in the bone marrow could help to elucidate its
precise role in hematopoiesis, immunity, and adipose tissue
development.
We were unable to detect LepR-dependent interactions in
mice in our micro-PET experiments in fat and at the hypothalamic
binding sites that are required for leptin’s role in regulating food
intake and energy expenditure. Based on the finding that we
could detect saturable binding of leptin in rhesus macaques in
the bone marrow at an injected dose of 0.006 mg/kg but not 0.1
mg/kg, we predict that an injected dose of less than 0.005 mg/
kg would be required to study LepR-dependent interactions in
mice (Table S1). In order to accomplish this in a micro-PET
imaging experiment in mice, with an injected dose of 5–10156 Cell Metabolism 10, 148–159, August 6, 2009 ª2009 Elsevier InMBq, a leptin derivative with a specific activity of at least 500–
1000 GBq/mmol would need to be achieved. This extraordinarily
high specific activity is not attainable with current radiochemical
techniques for protein labeling. Thus, we relied on ex vivo biodis-
tribution analysis to study LepR-dependent interactions in mice.
In these experiments, a much smaller relative dose of leptin was
injected (10–15 KBq corresponding to 0.003 mg/kg versus 1 mg/
kg in PET studies [Table S1]). Similarly, PET/CT analysis in rhesus
macaques requires a much smaller injected dose of tracer in
comparison with the size of the animal (0.005 mg/kg [Table S1]).
The very low brain uptake and biodistribution results are
largely consistent with previous leptin biodistribution studies
(Banks et al., 1996; Karonen et al., 1998; McMurtry et al., 2004;
Van Heek et al., 1996). This profile is not surprising, given the
small number of leptin binding sites predicted for the hypothal-
amus. It is noteworthy that, despite the fact that many of leptin’s
biologic outputs are mediated by hypothalamic leptin receptors,
such a small fraction of the total hormone produced is apparently
concentrated in this region (Figure 5C).
We also did not detect hypothalamic binding of leptin in PET
studies in monkeys, despite the fact that we were able to
observe saturable binding of leptin to bone marrow. This was
likely the result of the extraordinarily high signal in sphenoid
bone, which obfuscated any possible signal from the adjacent
hypothalamus. Similar studies of leptin binding to hypothalamus
in humans are less likely to be confounded by this, because the
human sphenoid is known to pneumatize into an air sinus during
development, with low uptake of the proliferation/bone marrow-
directed tracer 18F-fluorodeoxythymidine (FLT) in this region in
adults (Aoki et al., 1989; Buck et al., 2008). Thus, these studies
provide a rationale for initiating PET studies of leptin biodistribu-
tion in humans. If direct binding of leptin in brain can be demon-
strated in humans, further studies could also provide evidence
concerning whether there are differences in the rate of leptin
uptake in brain between lean and obese individuals, a possibility
that has been previously suggested (Caro et al., 1996).
In summary, here we report the use of two labeled tracers, 18F-
FBA-leptin and 68Ga-DOTA-leptin, for PET imaging in rodents
and primates. Our two tracers generate identical results, vali-
dating the authentic biodistribution of the hormone leptin
following systemic administration. Micro-PET imaging in mice
revealed that the uptake of leptin by the kidney requires the action
of the multiligand endocytic receptor megalin. Additionally, bio-
distribution analysis and PET imaging in rhesus macaques and
mice revealed a high level of uptake of leptin in tissues under-
going active hematopoiesis. The application of our tracers to
PET imaging in other systems, including in humans, could
provide further information about leptin physiology.
EXPERIMENTAL PROCEDURES
Synthesis of 68Ga-DOTA-Leptin and 18F-FBA-Leptin
A lysine-directed labeling approach using DOTA-NHS ester (Macrocyclics;
Dallas, TX) was employed. Briefly, to 100 ml mouse leptin solution at 13.1 mg/ml
(Amylin Pharmaceuticals; San Diego, CA) was added 162 ml metal-free (by che-
lex resin treatment, Bio-Rad) 100 mM sodium phosphate (pH 7.5) (final concen-
tration of 5 mg/ml). To this solution was added 100 equivalents of DOTA-NHS
(8.2mmol, 4.1 mg), and the pH was adjusted to 7.5 using 1 N NaOH. The reaction
proceeded for 3 hr at 4C, at which point it was purified by HPLC using a Hewlett
Packard 1100 series instrument and a Vydac C4 column (5 mm, 43 150 mm) onc.
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buffer B is 90% acetonitrile, 0.1% trifluoroacetic acid in water). The product
was characterized by electrospray ionization mass spectrometry (ESI-MS) on
a Sciex API 100 single quadrupole spectrometer, which indicated the incorpo-
ration of 2–6 DOTA moieties per leptin molecule. The solution was separated to
eight aliquots of DOTA-leptin and lyophilized. Prior to synthesis, the leptin was
resuspended in 40 ml of metal-free 15 mM HCl, and 10 ml of 1.2 M sodium
acetate (pH 4.5) was added.
DOTA-leptin was labeled using 68Ga eluted from a 68Ge/68Ga generator
(Isotope Products Laboratories; Burbank, CA) using a previously described
procedure (Hoffend et al., 2005) with modifications. We found that reproduc-
ible labeling results were obtained by eluting the generator the day prior to
labeling, presumably to remove impurities. The gallium generator was eluted
with 7 ml of 1 M metal-free HCl. The solution was diluted with 7 ml of concen-
trated HCl (trace metal grade, Fisher; Pittsburgh) and applied to 150 ml settled
volume of AG 1-X8 resin (Bio-Rad). The 68Ga was then eluted from the resin
using 300 ml 15 mM HCl and followed by 100 ml of 15 mM HCl. The dilute
acid solution was evaporated at 160C, and the 68Ga was subsequently resus-
pended in 40 ml of metal-free 15 mM HCl. The 68Ga solution was then added
to the DOTA-leptin solution (above) and incubated in a 35C water bath for
20 min. The solution was then centrifuged for 1 min at 10,0003 g, and the
supernatant was added to 2 ml of 0.1 M diethylenetriaminepenta-acetic acid
(DTPA). After 2 min, the solution was transferred to a Micro Bio-Spin Column
6 (Bio-Rad), which had been pre-equilibrated with PBS according to the manu-
facturer’s instructions. The 68Ga-DOTA-leptin was eluted from the column by
centrifuging at 10003 g for 4 min. Following elution, the solution was diluted to
an appropriate volume for injection in PBS (1 ml for rhesus monkey experi-
ments, 700 ml for two injections in mice) and filtered through a 0.22 mm filter.
The specific activity of the conjugate at the end of synthesis was 9.1 ±
4.2 GBq/mmol (SD, n = 30 syntheses) at greater than 90% pure, as determined
by radiochemical HPLC and instant TLC. The amount of total protein in the
reaction was determined by BCA assay (Pierce; Rockford, IL).18F-FBA-leptin
was prepared as previously described (Figure S1) (Flavell et al., 2008).
Luciferase reporter assay of LepRb activation was performed as previously
described (Flavell et al., 2008). Briefly, bioactivity of mouse recombinant leptin
(Amylin Pharmaceuticals) and semisynthetic derivatives was tested in dupli-
cate for every dilution using a 293 cell line stably transfected with LepRb
and a firefly luciferase gene under a STAT3-responsive element. After 24 hr,
cells were collected and luciferase activity measured in cell lysate using a
luciferase assay system (Promega; Madison, WI).
Cell Binding Experiment
Six aliquots of 20 million LepRb-STAT3-luciferase 293 cells (Flavell et al., 2008)
were resuspended in 300 ml HBSS. Approximately 1.43 105 counts per minute
of 68Ga-DOTA-leptin was added to each tube, with or without cold leptin (Amy-
lin Pharmaceuticals), at a final concentration of 1 mM. The cells were incubated
for 2 hr, centrifuged, and washed three times with HBSS. The radioactivity
associated with the cell pellets, assayed in triplicate, was then counted in
a gamma counter.
Mouse Studies
Megalinlox/loxApoECre and megalinlox/lox mice were obtained from Dr. T. Will-
now (Max-Delbrueck Center for Molecular Medicine; Berlin) (Leheste et al.,
2003). Urine samples for ELISA were collected at 16 weeks of age. Male
mice were imaged at 7 months of age. Rats used for PET scans were male
Sprague-Dawley rats purchased from Charles River (Wilmington, MA) and
imaged between 12 and 16 weeks of age. Ob/ob mice used for leptin bioac-
tivity assay were purchased from Jackson Laboratory and tested at 16 weeks
of age when mice were treated with continuous subcutaneous infusion of
mouse recombinant leptin or DOTA-leptin using mini osmotic pumps (Alzet;
Cupertino, CA) at the dose of 450 ng/hr for 10 days. Ob/ob-LepRD mice
were generated in our laboratory, crossing heterozygote mice for both the lep-
tin receptor null mutation (LepRD) and leptin gene mutation (ob). Ob/ob-LepRD
and ob/ob male mice (genotype was performed by Transnetyx, Inc.; Cordova,
TN) used for PET scans were imaged between 12 and 16 weeks of age. All
mouse studies were conducted under approved protocols of the Rockefeller
University and Weill Cornell Medical College.CeMicro-PET Imaging Experiments in Mice and Rats
In a typical micro-PET mouse experiment, 4–9 MBq of 18F-FBA-leptin or 68Ga-
DOTA-leptin tracer, corresponding to approximately 25 mg of leptin, was
injected in bolus via the tail vein. For rat imaging, 15–30 MBq was injected
via the tail vein. Male mice and rats were scanned for 1 hr under anesthesia
with ketamine-xylazine with continuous bed motion immediately after injection
using a micro-PET camera (TM 220, CTI Concord Microsystems, LLC; Knox-
ville, TN) with a bore size of 22 cm and an axial field of view (FOV) of 7.6 cm. The
resolution at the center of FOV is < 1.3 mm. 3D histograms of emission data
were generated (span3, rig difference 47) using dead time correction. Images
were reconstructed using an OSEM2D algorithm without any attenuation or
scatter correction. Regions of interest were drawn and images and time
activity curves were generated using PMOD biomedical image quantification
software (PMOD Technologies Ltd., Zu¨rich).
Biodistribution Experiments in Mice
Approximately 10–15 KBq of 125I-leptin (81.4 GBq/mmol, 20 ml of the solution
provided by the manufacturer) (PerkinElmer, New England Nuclear; Waltham,
MA) was diluted in 300 ml of sterile PBS and injected in the tail vein of the appro-
priate mouse strains, previously anesthetized with ketamine-xylazine, in the
presence of 50 ml of murine leptin solution (13.1 mg/ml, Amylin Pharmaceuti-
cals) or PBS. After 15 min, the animals were sacrificed, and tissues were
collected and weighed. Radioactivity associated with each sample was
counted in a gamma counter with corresponding standards and blanks and
residual activity from each injection. The total injected dose was computed
by preparing a standard of 20 ml of the manufacturers’ solution and subtracting
the residual dose remaining in the syringe postinjection and the radioactivity in
the tail of the animal.
Primate PET/CT Experiments
Subjects were three gonadally intact adult male rhesus monkeys (Macaca
mulatta). Subjects were approximately 10–14 years of age and weighed in
the range of 8–12 kg. Subjects were housed in a stable colony and were previ-
ously exposed to the experimental situation (e.g., pole and collar training,
transfer into transport cage, etc.).
On experiment days, the subjects were individually transported to the PET
center in a purpose-built transfer cage. They were then injected with ketamine
(10 mg/kg, intramuscular) and atropine (0.05 mg/kg, intramuscular). Subjects
were then intubated, and anesthesia was induced with isoflurane (3%).
Subjects’ vital signs (respiratory rate, heart rate, temperature, and pulse oxi-
metry) were monitored throughout; anesthesia was typically then maintained
at 1.5%–2.5% isoflurane for the remainder of the experiment. The subject
was placed supine on a heating pad (37C) in the bed of the PET scanner for
the remainder of the experiment. Primate PET/CT scans were performed using
a GE Discovery LS PET/CT scanner (GE Healthcare; Waukesha, WI). A low-
dose CT scan was obtained, and the scanner bed was moved into PET
position. Competing cold leptin (0.1 mg/kg; intravenous [i.v.] bolus) was
administered by a femoral i.v. catheter 5 min prior to injection of the radio-
tracer. Starting 10 min following an intravenous injection of 15 MBq of 68Ga-
DOTA-leptin or 18F-FBA-leptin, four sequential 20 min whole-body images
were obtained (four beds, 5 min each) in 3D acquisition mode. Images were
reconstructed using the FORE-Iterative reconstruction method. Following
completion of the transmission scan, isoflurane was discontinued, and the
subject was extubated when gagging reflex was observed. The subject was
carefully observed until recovery (which was rapid and uneventful, in all cases).
All experiments were conducted under approved protocols of the Rockefel-
ler University and Weill Cornell Medical College. Leptin ELISA, western blot-
ting, HPLC analysis of 68Ga-DOTA-leptin in vitro and in vivo, expression and
purification of rhesus leptin, and 125I-leptin degradation assay were performed
as described in the Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
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